Stockpolly
Search
MLYS · NASDAQ · Biotechnology

Mineralys Therapeutics (MLYS)

Develops lorundrostat for uncontrolled hypertension and related cardiorenal conditions.

$29.03
Pre-market−0.02 (−0.07%)
At close$29.05(+13.61%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
2628354560524447413845246
Research & development2224313954453838312424221
4456677810142125
Selling & marketing000000000000
General & administrative4456677810142125
Operating income−26−28−35−45−60−52−44−47−41−38−45−246
434443234665
Interest income434443234665
Other non-operating income−4−3−4−4−4−3−2−3−4−6−6−5
Income before tax−23−24−32−41−56−49−42−43−37−32−39−241
Net income from continuing operations−23−24−32−41−56−49−42−43−37−32−39−241
Net income−23−24−32−41−56−49−42−43−37−32−39−241
EPS, basic−$0.57−$0.61−$0.70−$0.83−$1.13−$0.98−$0.79−$0.66−$0.52−$0.40−$0.47−$2.85
EPS, diluted−$0.57−$0.61−$0.70−$0.83−$1.13−$0.98−$0.79−$0.66−$0.52−$0.40−$0.47−$2.85
Weighted average shares, basic404045495050536571818385
Weighted average shares, diluted404045495050536571818385
EBITDA−23−24−32−41−56−49−42−43−37−32−39−241
Depreciation & amortization000000000000
EBIT−23−24−32−41−56−49−42−43−37−32−39−241